Charles Reay Mackay
Founder at G2 Therapies Pty Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter Whitfeld | M | - |
G2 Therapies Pty Ltd.
 G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | - |
| Andrew Adamovich | M | - |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | - |
| Terri Faroe | F | - |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | - |
| Brad Rees | M | - |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | - |
| David Barda | M | - |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Michael Schubert | M | 80 |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | 13 years |
| Robert Sutherland | M | - |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Australia | 7 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Charles Reay Mackay
- Personal Network
